Identifying patients at risk for coronary heart disease; implications from trials of lipid-lowering drug therapy

摘要

Abnormal lipid levels contribute significantly to the risk of coronary heart disease (CHD), which is increased further in the presence of other risk factors. The association between elevated low- density lipoprotein (LDL) cholesterol and CHD risk is well established, and large primary and second- ary prevention studies of HMG-CoA reduces inhibitors (statins) have shown conclusively that lowering LDL cholesterol levels reduces CHD events and total mortality.